Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | GALR3 | O60755 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31361439 | 1.00 | ALOX15 (0.40) | ALOX15KDM1AKCNH2KDM1BNQO2 | |
| SCHEMBL855230 | 0.82 | KDM1A (0.48) | KDM1AKCNH2KDM1B | |
| SCHEMBL29666934 | 0.82 | KDM1A (0.48) | KDM1AKCNH2KDM1B | |
| SCHEMBL29987655 | 0.82 | PIM1 (0.41) | ALOX15ESR1ESR2ARPIM1 | |
| SCHEMBL1512796 | 0.82 | PIM1 (0.41) | ALOX15ESR1ESR2ARPIM1 | |
| SCHEMBL28694200 | 0.81 | ALOX15 (0.39) | ALOX15NQO2ESR1ESR2AR | |
| SCHEMBL28975669 | 0.81 | ALOX15 (0.39) | ALOX15KDM1AKCNH2KDM1BNQO2 | |
| SCHEMBL30129349 | 0.81 | ADRA2A (0.42) | ALOX15KDM1AKCNH2KDM1BNQO2 | |
| SCHEMBL27949463 | 0.81 | ALOX15 (0.39) | ALOX15NQO2ESR1ESR2ALOX12 | |
| SCHEMBL4589607 | 0.81 | ADRA2A (0.42) | ALOX15KDM1AKCNH2KDM1BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105085190-A | Preparing method of 2,6-difluoro-4-bromophenol | CECEP VALIANT CO LTD | 2015-11-25 | — | — | CN | claimed |
| US-20260116891-A1 | Oxazepin Derivative | TEIJIN PHARMA LTD (JP) | 2026-04-30 | — | — | US | disclosed |
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4700068-A1 | SILANE COMPOUND | Daikin Industries, Ltd. (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-20260049092-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-3941919-B1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | GENENTECH, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4568955-A1 | ANTIBACTERIAL COMPOUNDS | Blacksmith Medicines, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2005077892-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| WO-2004047751-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| EP-1214306-A1 | LIQUID CRYSTAL COMPOUNDS | Qinetiq Limited (GB) | 2002-06-19 | — | — | EP | disclosed |
| EP-1173170-A4 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1173170-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6265434-B1 | ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. | 2001-07-24 | — | — | US | disclosed |
| WO-2001021606-A1 | LIQUID CRYSTAL COMPOUNDS | QINETIQ LIMITED (GB) | 2001-03-29 | — | — | WO | disclosed |
| JP-2000309555-A | PRODUCTION OF p-BROMOPHENOL COMPOUND | KANTO DENKA KOGYO CO LTD | 2000-11-07 | — | — | JP | disclosed |
| WO-2000059503-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-0500210-A2 | Liquid crystal compounds and compositions | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 1992-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049092-A1 | ANTIBACTERIAL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, FPR1 | ALOX15 1523/4885KDM1A 2592/4885KCNH2 531/4885 |
| US-12344603-B2 | Pyrido-pyrimidinone and pteridinone compounds and methods of use | TYMP, TYMS, DPYD | ALOX15 1722/4885KDM1A 2560/4885KCNH2 4574/4885 |
| US-20260116891-A1 | Oxazepin Derivative | HCRTR2, HCRTR1, OXTR | ALOX15 915/4885KDM1A 2119/4885KCNH2 600/4885 |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BCL6B | ALOX15 1359/4885KDM1A 581/4885KCNH2 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.